There are multiple pharmacotherapy options for type 2 diabetes mellitus (T2DM) including injectable glucagon-like peptide 1 receptor agonists (GLP-1RA). EndoBarrier is an innovative impermeable liner implanted endoscopically into the proximal intestine for up to one year, before removal. We compare the cost-effectiveness of three strategies in patients with suboptimally controlled type 2 diabetes despite at least 6 months’ liraglutide: EndoBarrier combined with liraglutide; EndoBarrier without liraglutide; and liraglutide without EndoBarrier for the treatment of obese patients with T2DM from a National Healthcare perspective.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.